AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Rhea-AI Summary

Teva (NYSE: TEVA) announced interim real-world results from Part B of the IMPACT-TD Registry (Nov 7, 2025) showing patient-reported benefits after three months on AUSTEDO or AUSTEDO XR for tardive dyskinesia (TD).

In 27 adults, participants reported meaningful improvements in speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). The Abnormal Involuntary Movement Scale (AIMS) total motor score fell by a mean of -2.9. Among those taking concomitant mental health meds, 85% reported stable or improved mental health.

Positive

• Patient-reported improvement in speech/communication: 77%
• Patient-reported improvement in eating: 75%
• AIMS total motor score decreased by -2.9 at three months
• 85% reported stable or improved mental health with concomitant meds

Negative

• Small interim cohort of 27 adults limits generalizability
• Findings reported as interim Part B results, not final registry readout

Insights

Movement disorders clinical analyst

Interim real-world data show patient-reported functional gains and measurable motor improvement after three months on AUSTEDO/AUSTEDO XR.

These Phase 4 registry results link reductions in involuntary movements to better daily function: the AIMS total motor score fell by a mean of -2.9 after a three-month period, and patients reported meaningful improvement in speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). The analysis used a 30-question patient-reported scale (IMPACT-TD PRO) and included participants with common psychiatric comorbidities, which supports relevance to a typical real-world population.

The main dependencies and risks are small sample size (n=27) and interim status, which limit statistical certainty and generalisability; the reported AIMS change is described as "consistent with pivotal trials," but no p-values or confidence intervals are provided, so inferential strength remains unclear. Most participants on concomitant mental‑health medications reported stable or improved mental health (85%), which addresses a key safety/utility concern for this population.

Watch for the final Part B registry readout and larger sample follow-up to confirm durability and statistical significance over a longer horizon; expect meaningful updates when the registry moves beyond this three-month interim window or reports formal comparative statistics.

• In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XR
• Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved
• Teva is committed to truly understanding and empowering individuals living with TD to help improve their TD and regain their independence
  

PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to reductions in the severity of involuntary movements and improvements in patient-reported quality of life. The data were presented at the 2025 Neuroscience Education Institute Fall Congress, taking place November 6 – 9, 2025 in Colorado Springs, Colorado.

"The silent struggle of tardive dyskinesia, with its relentless, involuntary movements, can deprive patients of their quality of life and independence—real-world findings are so critical to inform how we innovate and improve the everyday lives of individuals living with this disease,” said Stacy Finkbeiner, Senior Medical Director, Movement Disorders & Psychiatry at Teva. “These data articulate patient experience and further validate clinical research showing how AUSTEDO or AUSTEDO XR can help people living with tardive dyskinesia improve their symptoms while maintaining their mental health, something we care deeply about in our mission at Teva to improve the lives of patients.”

The interim analysis of the IMPACT-TD Registry, a Phase 4 study, evaluated 27 adults with TD treated with AUSTEDO or AUSTEDO XR after a three-month period using IMPACT-TD PRO, a 30-question scale measuring patient-reported impact across 5 key areas. The study included patients with common comorbid psychiatric disorders, such as bipolar disorder (41%), anxiety disorder (37%), depression (26%), and schizophrenia (19%), reflecting a diverse, real-world patient population.

Key results revealed:

• Patient-reported meaningful improvement after three months on AUSTEDO or AUSTEDO XR across several areas, including speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%).
• At three months, the total motor score on the Abnormal Involuntary Movement Scale (AIMS) showed a mean decrease of -2.9, indicating a notable reduction in the severity of uncontrolled movements consistent with what was previously seen in pivotal trials.
• Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their underlying mental health condition remained stable or improved based on the Patient Global Impression of Severity (PGIS) scale.
  
  

While Part A of the IMPACT-TD Registry demonstrated the broad impact TD has on individuals beyond physical movements, these initial findings from Part B reflect patient-reported improvements in everyday tasks like speaking, eating, and other activities of daily living as a result of movement reduction with AUSTEDO or AUSTEDO XR.

About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.^1,2,3

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets
AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE
AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington’s disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

1. Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Hauppauge, NY: Nova Science Publishers. 2013:235-258.
2. Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.
3. Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Accessed May 4, 2023.
   
   

Teva Media Inquiries	TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries	TevaIR@Tevapharm.com

FAQ

What did Teva announce about AUSTEDO and AUSTEDO XR on November 7, 2025 (TEVA)?

Teva reported interim IMPACT-TD Part B data showing patient-reported improvements and an AIMS motor-score mean decrease of -2.9 after three months.

How many patients were included in the IMPACT-TD Part B analysis for TEVA?

The interim analysis evaluated 27 adults with tardive dyskinesia treated with AUSTEDO or AUSTEDO XR for three months.

What quality-of-life areas improved for patients on AUSTEDO or AUSTEDO XR in the TEVA data?

Patients reported improvements in speech/communication (77%), eating (75%), psychosocial impact (65%), and activities of daily living (59%) after three months.

Did AUSTEDO or AUSTEDO XR affect patients' mental health in the TEVA IMPACT-TD results?

85% of participants taking AUSTEDO or AUSTEDO XR with mental health medications reported their underlying mental health remained stable or improved.

How should investors interpret the AUSTEDO IMPACT-TD Part B results for TEVA stock near term?

Results show early real-world symptom and quality-of-life signals, but they are interim from a 27-patient cohort and may have limited near-term market impact.